Can a cancer drug slow down a rare leukemia?

NCT ID NCT03722407

Ongoing Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 4 times

Summary

This study tests the drug ruxolitinib (Jakafi) in 29 people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if the drug can improve blood counts, shrink the cancer, or delay its turning into a more aggressive leukemia. Researchers are also checking how safe the drug is and how long any benefits last.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib (also known as Jakafi)
What this could lead to: If successful, this could offer a new treatment option to control CMML and delay its progression to acute leukemia.
What could go wrong: This is a small, early-phase trial with only 29 participants, so results may not apply broadly. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelomonocytic leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOMONOCYTIC LEUKEMIA LEUKEMIA

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21231, United States
Weill Medical College of Cornell University

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.